Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lyrica, Other Key Products Upbeat in FY2012 Despite NHI Price Revision: Pfizer Japan Pres. Umeda
December 13, 2012
- Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
- Astellas Initiates PIII Study of Oral Renal Anemia Treatment in US, Europe
December 13, 2012
- Importance of Alliances Increasing in Competitive Diabetes Drug Market
December 13, 2012
- About 50% of FLT3-ITD Positive Patients Achieve CRc in PII Study for Quizartinib: Astellas
December 13, 2012
- Kaken Initiates Voluntary Partial Recall of Empynase-P Tablets 18000
December 13, 2012
- UMN Pharma Listed on TSE Mothers, Sets Midterm Plan Target to Be in Black
December 13, 2012
- Domestic Drug Makers Need to Break from Closed Innovation and Promote Open Innovation: Prof. Teranishi of Kyoto Univ. MIC
December 13, 2012
- [Data] Sales of Takeda’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Daiichi Sankyo’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Otsuka HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Astellas’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Eisai’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Dainippon Sumitomo’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Mitsubishi Tanabe’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Taisho HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kyorin HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Shionogi’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Ono’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Santen’s Mainstay Products in 1st Half of FY2012
December 13, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…